Globus Medical earnings release, August 6, 2026

Globus Medical Inc (GMED) · Form 8-K, Item 2.02 · Filed · SEC filing

Globus Medical Reports Second Quarter 2026 Results

AUDUBON, PA., August 6, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026.

Second Quarter 2026:

• Worldwide net sales were $789.6 million, an increase of 5.9%, or an increase of 5.6% on a constant currency basis.

• GAAP net income for the quarter was $151.6 million.

• GAAP diluted earnings per share (“EPS”) was $1.10, a decrease of 26.2%, primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. Non-GAAP diluted EPS was $1.34, an increase of 55.8%.

“Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro, driven by share gains across a majority of our underlying businesses, most notably US Spine, growing 7% and International Spine, growing 14% as-reported and 12% on a constant currency basis,” commented Keith Pfeil, President and Chief Executive Officer. “The depth of our product portfolio and exclusive selling model positions us to lead with innovation and commercial outreach, driving our ability to grow share over the long-term. Our priority remains centered on achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.”

“US Spine, again, led the way in growth for the organization, marking our fifth straight quarter of above-market revenue growth, with continued strength across our entire product portfolio. This broad-based growth, paired with adjusted gross margin expansion of 200 basis points compared to the second quarter of the prior year, drove record second quarter non-GAAP net income and diluted earnings per share,” said Kyle Kline, Chief Financial Officer. “The strength of our second-quarter performance reflects disciplined execution across the business, including margin expansion, operating leverage, and synergy realization, which position us to deliver sustained earnings growth, and enhanced shareholder returns throughout the year.”

Worldwide net sales for the second quarter of 2026 were $789.6 million, an as-reported increase of 5.9% over the second quarter of 2025. U.S. net sales for the second quarter of 2026 increased by 3.0% compared to the second quarter of 2025. International net sales increased by 18.0% over the second quarter of 2025 on an as-reported basis and increased by 16.2% on a constant currency basis.

GAAP net income for the second quarter of 2026 was $151.6 million, a decrease of 25.3% over the same period in the prior year. The decrease in GAAP net income was primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. GAAP diluted EPS for the second quarter was $1.10, compared to $1.49 for the second quarter of 2025, a decrease of 26.2%. Non-GAAP diluted EPS for the second quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.34, compared to $0.86 in the second quarter of 2025, an increase of 55.8%.

2026 Annual Guidance

The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.95 to $5.05 from the previous range of $4.70 to $4.80.

Conference Call Information

Globus Medical will hold a teleconference to discuss its 2026 second quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news-events/events-webcasts.

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.

Non-GAAP Financial Measures... (truncated)es non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.

In addition, for the period ended June 30, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non-recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends.

Additionally, for the period ended June 30, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business revenue growth, excluding the contribution from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide insight to how the Company is performing without the impact of our most recent acquisition.

Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP gross profit, free cash flow, constant currency net sales growth, base business revenue growth, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three months ended June 30, 2026.

We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition-related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments, and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income.

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited) (In thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net sales789,612745,3421,549,4661,343,463
Cost of Sales and Operating expenses:Cost of sales (exclusive of amortization of intangibles)241,439248,765475,505444,162
Cost of Sales and Operating expenses:Research and development36,32139,95472,83173,016
Cost of Sales and Operating expenses:Selling, general and administrative286,823303,622584,598546,421
Cost of Sales and Operating expenses:Amortization of intangibles29,56030,18959,08658,991
Cost of Sales and Operating expenses:Acquisition-related costs11,08033,15617,45734,213
Cost of Sales and Operating expenses:Restructuring costs1,95713,5477,16913,547
Cost of Sales and Operating expenses:Operating income/(loss)182,43276,109332,820173,113
Other income/(expense), netInterest income/(expense), net7,07469312,5082,374
Other income/(expense), netForeign currency transaction gain/(loss)-86038-2,9734,308
Other income/(expense), netBargain purchase gain110,5611,118110,561
Other income/(expense), netOther income/(expense)1,1717723,4181,485
Other income/(expense), netTotal other income/(expense), net7,385112,06414,071118,728
Other income/(expense), netIncome/(loss) before income taxes189,817188,173346,891291,841
Other income/(expense), netIncome tax provision/(benefit)38,248-14,67371,02013,533
Other income/(expense), netNet income/(loss)151,569202,846275,871278,308
Other comprehensive income/(loss), net of tax:Unrealized gain/(loss) on marketable securities-5512-1,711317
Other comprehensive income/(loss), net of tax:Foreign currency translation gain/(loss)-2,65712,404-2,43916,783
Other comprehensive income/(loss), net of tax:Total other comprehensive income/(loss), net of tax-3,20812,406-4,15017,100
Other comprehensive income/(loss), net of tax:Comprehensive income/(loss)148,361215,252271,721295,408
Earnings per share:Basic1.121.52.042.05
Earnings per share:Diluted1.11.4922.01
Weighted average shares outstanding:Basic135,054135,205135,209135,981
Weighted average shares outstanding:Diluted137,384136,499137,787138,137

Income Statement

Three Months Ended June 30, — Non-GAAP Adjusted EBITDA Reconciliation Table: (In thousands, except percentages)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income/(loss)151,569202,846275,871278,308
Interest (income)/expense, net-7,074-693-12,508-2,374
Provision for income taxes38,248-14,67371,02013,533
Depreciation and amortization70,08470,631140,205136,705
EBITDA252,827258,111474,588426,172
Stock-based compensation expense13,38313,25825,99726,310
Provision for litigation, net62-2,621196-3,908
Merger and acquisition-related costs (1)11,29040,39317,73141,499
Net (gain) loss from strategic investments-364-1,248-1,189-1,309
Non-cash acquisition-related foreign currency impacts-119-8,565-217-12,337
Restructuring costs2,76019,9159,14720,649
Bargain purchase gain-110,561-1,118-110,561
Adjusted EBITDA279,839208,682525,135386,515
Net income/(loss) as a percentage of net sales19.2%27.2%17.8%20.7%
Adjusted EBITDA as a percentage of net sales35.4%28.0%33.9%28.8%

Income Statement

Three Months Ended June 30, — Non-GAAP Net Income Reconciliation Table: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income/(loss)151,569202,846275,871278,308
Provision for litigation, net62-2,621196-3,908
Amortization of intangibles29,56030,18959,08658,991
Merger and acquisition -related costs (1)11,29040,39317,73141,499
Net gain/(loss) on strategic investments-364-1,248-1,189-1,309
Non-cash acquisition-related foreign currency impacts-119-8,565-217-12,337
Restructuring costs2,76019,9159,14720,649
Bargain purchase gain-110,561-1,118-110,561
Provision for income tax benefit from non-recurring tax adjustments-34,815-34,815
Tax effect of adjusting items-10,464-18,751-20,317-24,907
Non-GAAP net income/(loss)184,294116,782339,190211,610

Income Statement

Three Months Ended June 30, — Non-GAAP Gross Profit Reconciliation Table: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net sales789,612745,3421,549,4661,343,463
Cost of sales (exclusive of amortization of intangibles)241,439248,765475,505444,162
Amortization of intangibles21,09024,64342,22146,851
Gross Profit527,083471,9341,031,740852,450
Amortization of inventory fair value step up5,9676,016
Amortization of intangibles21,09024,64342,22146,851
Adjusted Gross Profit548,173502,5441,073,961905,317
Gross Profit % of Net Sales66.8%63.3%66.6%63.5%
Adjusted Gross Profit % of Net Sales69.4%67.4%69.3%67.4%

Balance Sheet

December 31, — (unaudited) (In thousands, except share and per share values)

June 30, – 2026December 31, – 2025
Cash and cash equivalents507,745526,156
Short-term marketable securities87,39731,087
Accounts receivable, net of allowances $44,371 and $33,434, respectively692,176678,938
Inventories810,897759,277
Prepaid expenses and other current assets70,19565,426
Income taxes receivable47,10264,727
Total current assets2,215,5122,125,611
Property and equipment, net533,528564,452
Operating lease right of use assets59,15563,786
Long-term marketable securities245,35871,819
Intangible assets, net692,624745,064
Goodwill1,438,2161,435,033
Other assets79,23878,781
Deferred income taxes224,627218,215
Total assets5,488,2585,302,761
Current liabilities:Accounts payable106,94198,852
Current liabilities:Accrued expenses300,728333,586
Current liabilities:Operating lease liabilities14,38514,738
Current liabilities:Income taxes payable6,0364,155
Current liabilities:Business acquisition liabilities23,27619,513
Current liabilities:Deferred revenue27,98127,655
Current liabilities:Total current liabilities479,347498,499
Current liabilities:Business acquisition liabilities, net of current portion82,11381,995
Current liabilities:Operating lease liabilities96,807103,918
Current liabilities:Deferred income taxes and other tax liabilities42,34223,756
Current liabilities:Other liabilities19,04621,343
Current liabilities:Total liabilities719,655729,511
Equity:Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 111,822,190 and 112,625,126 shares at June 30, 2026 and December 31, 2025, respectively112113
Equity:Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares at June 30, 2026 and December 31, 2025, respectively2222
Equity:Additional paid-in capital3,230,1863,169,812
Equity:Accumulated other comprehensive income/(loss)11,19615,346
Equity:Retained earnings1,527,0871,387,957
Equity:Total equity4,768,6034,573,250
Equity:Total liabilities and equity5,488,2585,302,761

Cash Flow

Six Months Ended June 30, — (unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income275,871278,308
Adjustments to reconcile net income to net cash provided by operating activities:Bargain purchase gain-1,118-110,561
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization139,355136,284
Adjustments to reconcile net income to net cash provided by operating activities:Provision for excess and obsolete inventory9,79510,933
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of acquisition accounting fair value step up12,673
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense26,00026,823
Adjustments to reconcile net income to net cash provided by operating activities:Allowance for expected credit losses10,3984,554
Adjustments to reconcile net income to net cash provided by operating activities:Change in fair value of business acquisition liabilities16,0595,389
Adjustments to reconcile net income to net cash provided by operating activities:Change in deferred income taxes15,748-41,236
Adjustments to reconcile net income to net cash provided by operating activities:(Gain)/loss on disposal of assets, net5,5586,131
Adjustments to reconcile net income to net cash provided by operating activities:Payment of business acquisition-related liabilities-2,596-15,764
Adjustments to reconcile net income to net cash provided by operating activities:Net (gain)/loss from foreign currency adjustment218-11,342
(Increase) decrease in:Accounts receivable-27,21120,395
(Increase) decrease in:Inventories-44,551-11,722
(Increase) decrease in:Prepaid expenses and other assets-459852
Increase (decrease) in:Accounts payable5,389-4,085
Increase (decrease) in:Accrued expenses and other liabilities-35,738-13,841
Increase (decrease) in:Income taxes payable/receivable19,387-38,626
Increase (decrease) in:Net cash provided by/(used in) operating activities412,105255,165
Cash flows from investing activities:Purchases of marketable securities-254,013-1,750
Cash flows from investing activities:Sales and maturities of marketable securities21,483174,238
Cash flows from investing activities:Purchases of property and equipment-72,783-82,665
Cash flows from investing activities:Acquisition of businesses, net of cash acquired and purchases of intangible and other assets-6,409-257,546
Cash flows from investing activities:Net cash provided by/(used in) investing activities-311,722-167,723

Cash Flow

Three Months Ended June 30, — Non-GAAP Free Cash Flow Reconciliation Table: (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net cash provided by operating activities209,74277,865412,105255,165
Purchases of property and equipment-33,168-46,562-72,783-82,665
Free cash flow176,57431,303339,322172,500
Full release

Safe Harbor Statements... (truncated)“intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.